Literature DB >> 11180447

Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.

D F Moore1, N Chatterjee, D Pee, M H Gail.   

Abstract

Wacholder et al. [1998: Am J Epidemiol 148:623-629] and Struewing et al. [1997: N Engl J Med 336:1401-1408] have recently proposed a design called the kin-cohort design to estimate the probability of developing disease (penetrance) associated with an autosomal dominant gene. In this design, volunteers (probands) agree to be genotyped and one also determines the disease history (phenotype) of first-degree relatives of the proband. They used this design to estimate that the chance of developing breast cancer by age 70 in Ashkenazi Jewish women who carried mutations of the genes BRCA1 or BRCA2 was 0.56, a figure that was lower than previously estimated from highly affected families. The method that they used to estimate the cumulative risk of breast cancer, while asymptotically correct, does not necessarily produce monotone estimates in small samples. To obtain monotone, weakly parametric estimates, we consider separate piecewise exponential models for carriers and non-carriers. As the number of intervals on which constant hazards are assumed increases, however, the maximum likelihood score equations become unstable and difficult to solve. We, therefore, developed alternative pseudo-likelihood procedures that are readily solvable for piecewise exponential models with many intervals. We study these techniques through simulations and a re-analysis of a portion of the data used by Struewing et al. [1997] and discuss possible extensions. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11180447     DOI: 10.1002/1098-2272(200102)20:2<210::AID-GEPI4>3.0.CO;2-I

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  3 in total

1.  Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.

Authors:  Bhramar Mukherjee; John Oliver Delancey; Leon Raskin; Jessica Everett; Joanne Jeter; Colin B Begg; Irene Orlow; Marianne Berwick; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Hoda Anton Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Lynn From; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

2.  Estimation of genotype relative risks from pedigree data by retrospective likelihoods.

Authors:  Daniel J Schaid; Shannon K McDonnell; Shaun M Riska; Erin E Carlson; Stephen N Thibodeau
Journal:  Genet Epidemiol       Date:  2010-05       Impact factor: 2.135

3.  Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.

Authors:  Phuong L Mai; Nilanjan Chatterjee; Patricia Hartge; Margaret Tucker; Lawrence Brody; Jeffery P Struewing; Sholom Wacholder
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.